WO2005002595A1 - 点眼用組成物 - Google Patents
点眼用組成物 Download PDFInfo
- Publication number
- WO2005002595A1 WO2005002595A1 PCT/JP2004/008739 JP2004008739W WO2005002595A1 WO 2005002595 A1 WO2005002595 A1 WO 2005002595A1 JP 2004008739 W JP2004008739 W JP 2004008739W WO 2005002595 A1 WO2005002595 A1 WO 2005002595A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ophthalmic composition
- composition according
- contact lens
- nonionic surfactant
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Definitions
- the present invention relates to an ophthalmic composition, and particularly to an ophthalmic composition that can advantageously prevent protein adhesion when wearing a contact lens and effectively improve the symptoms of dry eye.
- the present invention relates to a composition for use.
- an ophthalmic solution that can prevent the protein from adhering to and accumulating on the contact lens and advantageously eliminate the symptoms of dry eye is desired not only by contact lens wearers but also by practitioners. It is rare.
- Patent Document 1 discloses that although it is not an ophthalmic solution, citrate or the like is used as an active ingredient having an effect of preventing protein adhesion. A method for cleaning a contact lens using a cleaning solution containing is described.
- citrate has a strong negative charge and is relatively low in molecular weight, so it is highly cytotoxic and easily adsorbs to contact lenses. There is an inherent problem that eye damage is likely to occur. Further, even if such a solution containing citric acid as a detergent is instilled, the effect of shortening the residence time on the cornea cannot be sufficiently obtained.
- Patent Documents 2 and 3 propose a contact lens agent containing alginic acid or alginic acid, and it is clear that the alginic acid and the like improve the cleaning properties and make it difficult for protein stains to adhere. Has been. However, these publications do not disclose any means for resolving the symptoms of dry eye.
- Patent Document 1 Japanese Patent Publication No. Hei 8-503084
- Patent Document 2 Japanese Patent Application Laid-Open No. 7-157747
- Patent Document 3 Japanese Patent Application Laid-Open No. 2001-228445
- the present invention has been made in the background of vigorous circumstances, and a problem to be solved is that the symptoms of dry eye can be advantageously eliminated over a long period of time.
- it is intended to provide an ophthalmic composition that effectively suppresses the attachment and accumulation of protein to a contact lens when the contact lens is worn, and realizes an excellent feeling in use.
- the inventors of the present invention have conducted intensive studies to solve such problems, and as a result, have found that at least one of alginic acid, alginate, diurangam, and pectin has a nonionic property.
- a surfactant By combining with a surfactant and adjusting the tonicity or the osmotic pressure so as to be lower than the tonicity or the osmotic pressure of ordinary tears, the symptoms of dry eye are advantageous for a long time. It has been found that it is possible to eliminate or alleviate the problem and to effectively prevent the generation of a foreign-body sensation due to the contact lens and the attachment of protein to the contact lens when the contact lens is worn.
- a first aspect of the present invention is that alginic acid and / or a salt thereof, diperam gum, and alginic acid are contained in an aqueous medium.
- Pectin comprising at least one or more compounds selected from the group consisting of Pectin and a nonionic surfactant, and having a tonicity of 0.5 w / v% or more, calculated as An ophthalmic composition comprising less than 9 w / v%.
- At least one compound selected from the group consisting of alginic acid and / or a salt thereof, dielan gum, and pectin comprises: 001w / w%-10. Ow / w.
- the nonionic surfactant is contained at a ratio of 0.1 Olw / w% -5.OwZw%.
- a polyoxyethylene-polyoxypropylene block copolymer or polyoxyethylene sorbitan monoolate can be suitably used as the nonionic surfactant.
- the hydroxypropylmethylcellulose power S is preferably further contained.
- the hydroxypropylmethyl cellulose is contained in a ratio of 0.01 w / w% -5.Ow / w%.
- the nonionic surfactant has a surface tension of 25 ° C. in an aqueous solution containing 0.1% w / w% of the nonionic surfactant. , 55 m 2, m or less will be suitably used.
- the above-described ophthalmic composition has a function of effectively suppressing protein attachment, and has an adverse effect on contact lenses. From the viewpoint that it is not particularly desirable, it is desirable to use it as an eye drop for a contact lens, particularly, an eye drop that is applied while wearing a contact lens.
- the invention's effect is not particularly desirable.
- At least one of alginic acid and / or a salt thereof, dielan gum, and pectin, which are anionic polysaccharides, is used.
- the charged protein is less likely to adhere to the contact lens being worn, which effectively prevents protein from adhering and accumulating.
- these compounds are polymers, they do not adversely affect the physical properties and shape of the contact lens, which are difficult to be taken into the material of the contact lens.
- Alginic acid and Z or a salt thereof, dilan gum, and pectin are characterized in that they are gelated (increased in viscosity) by cations such as Ca 2+ ions in tear fluid. Due to the increase in viscosity (increase in viscosity), the residence time on the cornea after instillation is prolonged, and the effect of the ophthalmic composition according to the present invention is maintained for a long time. Therefore, for example, when a drug is blended in the ophthalmic composition according to the present invention, there is also obtained an advantage that the drug stays on the cornea and the contact time becomes longer.
- At least one compound of alginic acid and / or a salt thereof, diperam gum and pectin is used in combination with a nonionic surfactant, so that the By the interaction, at least one compound of alginic acid and / or a salt thereof, dielan gum, and pectin, which play a role in protecting the mucin layer, can be uniformly distributed throughout the cornea and conjunctiva. For this reason, uniform gelling can be performed without causing unevenness, and after instillation, a uniform gel-like film is formed on the regular surface. This does not lead to unstable vision due to unevenness. Symptoms such as dry feeling and discomfort can be advantageously eliminated.
- tear fluid has a three-layer structure consisting of a mucin layer, an aqueous layer, and an oil layer in order from the corneal side.
- a mucin layer affects the dryness of the eyes and the occurrence of eye disease ,It is said.
- composition for eye drops according to the present invention has a tonicity (osmotic pressure) of normal tear fluid, ie, 0.9 wZv% (about 285 m ⁇ smZkg in terms of sodium salt) in terms of sodium chloride. ),
- the osmotic pressure of tears raised by dry eye is appropriately reduced, and the dry feeling is advantageously reduced.
- the symptoms of dry eye can be extremely effectively eliminated over a long period of time, and therefore, it is much better than before. This gives the user a feeling of use.
- adhesion and accumulation of proteins on the contact lens can be advantageously suppressed.
- polyoxyethylene-polyoxypropylene block copolymer or polyoxyethylene sorbitan monoolate which has extremely low eye irritation and a very low possibility of adsorption to a contact lens. As a result, safety is further enhanced.
- the wettability and the moisturizing property are advantageously improved by the thickening action, and the effect of moisturizing the eyes is obtained.
- the effect of the active ingredient of the ophthalmic composition is further maintained, so that a more excellent feeling in use is realized.
- the surface active action of hydroxypropylmethylcellulose is also exerted, so that more uniform gelling can be realized and the cleaning effect can be advantageously obtained.
- the effect of hydroxypyrumethylcellulose is effectively realized.
- the effect of the nonionic surfactant is more effectively exhibited.
- the contact lens when used as an ophthalmic solution for a contact lens, the contact lens may be formulated with at least one compound of alginic acid and / or a salt thereof, diperam gum, and pectin. The effect of preventing protein adhesion is also exhibited, and the function of the ophthalmic composition according to the present invention can be maximized.
- the powerful ophthalmic composition according to the present invention mainly comprises an aqueous medium, and comprises (A) alginic acid and / or a salt thereof, diperam gum, and vectin as essential components. At least one compound selected from the group and (B) a nonionic surfactant are contained in combination, and the tonicity is adjusted to a specific value. It has a great feature in that it is adjusted to be lower than the teariness of tears.
- the ophthalmic composition according to the present invention has a tonicity (osmotic pressure) of 0.5 w / v% or more and less than 0.9 w / v% in terms of sodium chloride.
- the sodium chloride concentration is adjusted to be the same as the tonicity of the aqueous sodium chloride solution in the range of 0.5 w / v% or more and less than 0.9 w / v%. .
- the tears due to dry eye The increase in tonicity is advantageously improved, so that dry feeling and discomfort are effectively reduced, and excellent feeling of use is obtained.
- the tonicity is 0.5w in terms of sodium chloride. If it is less than 10%, the tonicity is too low, which may cause eye irritation. If it is 0.9w / v% or more, the effect of reducing the dryness of the eyes is low. Within the range as described above, it is more desirable to adjust to a tonicity of about 0.8 w / v% in terms of sodium chloride by adopting such a tonicity. Eye symptoms will be further improved.
- alginic acid is a linear polysaccharide composed of two types of peronic acids, D-mannuronic acid and L-guluronic acid, and a salt thereof.
- examples include sodium alginate, potassium alginate and the like.
- Gellan gum is composed of D-gnorecose, D-glucuronic acid, and L-rhamnose, which are produced outside the cells by aerobic fermentation using Pseudomonas elodea as a carbon source using glucose as a carbon source. It is a polysaccharide used as sugar.
- pectin is D-galataturonic acid A polysaccharide that is linearly linked by four bonds.
- alginic acid and / or its salt, diperam gum, and vectin are all anionic high molecular polysaccharides having a carboxyl group, and in the present invention, one or more of these are used. Is used by appropriately selecting two or more.
- the powerful A component acts as a protein adhesion inhibitor. More specifically, since the above-mentioned A component has a larger negative charge than that of the contact lens material, the protein in the tear is attracted to the force and the A component, which allows Attachment and accumulation of protein stains on the contact lenses can be extremely effectively suppressed. In addition, since the component A is a high molecular compound, it does not adversely affect the physical properties and shape of the contact lens, which is difficult to be taken into the inside of the contact lens.
- Alginic acid and Z or a salt thereof, dilan gum, and pectin all have a feature that they are partially ion-crosslinked by a cation such as Ca 2+ and gelled (increased viscosity). Therefore, in the present invention, the compound also functions as a gelling agent. That is, when an ophthalmic composition containing at least one compound of alginic acid and / or a salt thereof, dielan gum, and pectin is instilled, the ophthalmic composition is affected by calcium ions and the like present in tears. Gelation (high-viscosity dangling) occurs on the Kyular surface. The gelation (higher viscosity) advantageously increases the residence time of the ophthalmic composition.
- the content of the above-mentioned component A is appropriately set, if the content is too small, gelation does not sufficiently occur in the ocular surface, and the effect due to gelation does not occur. Where it may not be possible to obtain it, on the contrary, if it is too much, eye irritation may be caused or gel formation may become too strong and visual acuity after instillation may become unstable. Therefore, it is desirable that the composition is contained in the ophthalmic composition preferably in the range of 0.001w / w% -10.Ow / w, more preferably 0.1lw / w% -5.Ow / w%. Les ,.
- nonionic surfactant (B) used as another one of the essential components of the present invention those which have high safety to the living body and are ophthalmically acceptable , Which Can be advantageously used, but low-molecular nonionic surfactants are easily incorporated into the contact lens, and high-molecular nonionic surfactants are therefore desirable. Les ,.
- these polymeric nonionic surfactants in particular, the irritation to the eyes is extremely low, and the possibility of adsorption to contact lenses is lower and the reason is safer.
- polyoxypropylene block copolymer or polyoxyethylene sorbitan monoolate (polysorbate 80) is particularly advantageously used.
- the A component that plays a role in protecting the mucin layer by interacting with the mucin layer which is considered to affect the dry feeling of the eye, is added to the cornea and the conjunctiva as a whole. Can be uniformly distributed. As a result, a uniform gel-like film (gel layer) is formed on the spherical surface. In addition, since the uniform gel layer is formed in this manner, the symptoms of dryness and discomfort that do not cause visual instability such as image distortion can be advantageously eliminated.
- the active ingredient of the ophthalmic composition is applied to the back side (base curve side) of the contact lens, that is, between the cornea and the contact lens, by a strong nonionic surfactant. , And also effectively removes greasy dirt attached to the cornea and the contact lens. Further, the water wettability of the contact lens surface is also improved, and the occurrence of various symptoms such as blurred eyes, fogging of the contact lens, and a feeling of foreign matter can be advantageously prevented.
- an aqueous solution containing 0.1 lw / w% of a nonionic surfactant is particularly preferable.
- the lower limit is not particularly limited, since it is feared that the tear oil layer is destroyed, the lower limit should be 35 mNZm or more.
- the content of the component B if the content is too small, it may not be possible to form a uniform gel layer at the time of gelling the component A on the molecular surface. On the other hand, if the amount is too large, it may cause eye irritation or cause a problem in eye safety such as an influence on contact lens standards. 01w / w%-5.0w / w%, more preferably 0.05 w / w%-1.0wZw% is desirable.
- hydroxypropylmethylcellulose when (C) hydroxypropylmethylcellulose is further contained in addition to the above-mentioned component A and component B, wettability and moisturizing effect are obtained due to its thickening action.
- the properties are advantageously improved, the eyes are moistened, and the effects of the active ingredients of the ophthalmic composition are further maintained, so that a more excellent feeling of use is obtained.
- due to the surfactant effect of hydroxypropyl methylcellulose uniform gelling and washing effects can be obtained.
- any one that has high safety to a living body and is ophthalmically acceptable and has no influence on the shape and physical properties of a contact lens is advantageous. Can be used.
- the content of the component C is too small, the effect of the addition cannot be sufficiently obtained, and when the content is too large, the viscosity of the ophthalmic composition becomes too high and the feeling of use becomes poor. From the viewpoint of lowering, it is desirable to set within the range of 0.01 w / w%-5.0 w / w%, more preferably 0.05 w / w% -l. 0 w / w% .
- the ophthalmic composition according to the present invention may further comprise, if necessary, one of various additive components used in general eye drops, in addition to the components described above. There is no problem even if two or more kinds are appropriately selected and added at a normal addition ratio. In addition, it is preferable that such added components have high safety to the living body and are sufficiently ophthalmologically acceptable and do not affect the shape or physical properties of the contact lens. Use within the quantitative range that meets those requirements Therefore, various functions according to the added components can be advantageously imparted to the ophthalmic composition without inhibiting the effect of the present invention at all.
- the ophthalmic composition of the present invention in order for the ophthalmic composition of the present invention to advantageously exhibit a disinfecting effect or a bactericidal effect on the eyes and contact lenses, and furthermore an antiseptic and preservative effect of the ophthalmic composition.
- An antiseptic or a bactericide having an antiseptic effect or a bactericidal effect is added.
- such antiseptics and bactericides are desired to have an antiseptic or bactericidal effect and excellent compatibility with eyes and contact lenses, as well as those which are unlikely to cause allergies and other obstacles.
- Appropriate ones are selected from various types known for mackerel, and used alone or in combination.
- the preservatives include, for example, sorbic acid, potassium sorbate, benzoic acid or a salt thereof, ethyl para-hydroxybenzoate, butyl para-oxybenzoate, propyl para-oxybenzoate, propyl para-benzoate, methyl chloro-benzoate, chloro acid Butanol, perborate such as perboric acid or sodium perborate, and the like.
- the disinfectant include a biguanide disinfectant such as polyhexamethylene biguanide (PHMB) and a quaternary ammonium salt disinfectant such as polyquaternium.
- the ophthalmic composition according to the present invention may be used as a single-use single-dose type, or disclosed in Japanese Patent Application Laid-Open No. 2002-80055. It is also possible to use as a multi-dose type using a discharge container with a filter as disclosed
- the viscosity can be adjusted by adding the above-mentioned component C, but a thickening agent or a thickener other than the component C is added. It is also possible.
- a thickening agent or a thickening agent include various gums such as polysaccharides such as chondroitin sulfate, hyanolenoic acid, dalconic acid and salts thereof, mucopolysaccharides, and heteropolysaccharides.
- Synthetic organic polymer compounds such as polybutyl alcohol, poly-N-butylpyrrolidone, polyethylene glycol, polypropylene glycol, and polyacrylamide; hydroxyethinoresenorelose, canoleboxy methinoresenorelose, methinoresenolace mouth And the like; cellulose derivatives; and starch derivatives.
- an osmotic pressure adjusting agent is appropriately added so that the tonicity or the osmotic pressure has the above-mentioned values.
- the osmotic pressure adjusting agent used for adjusting the tonicity or the osmotic pressure includes sodium salt, potassium salt, sugars, sugar alcohols, polyhydric alcohols, ethers thereof, and esters thereof. At least one compound power S selected from the group will generally be used.
- the pH value of the ophthalmic composition is too high or too low, it may cause irritation to the eyes or cause eye damage.
- a pH adjuster used for such pH adjustment sodium hydroxide, hydrochloric acid, or the like is used.
- a buffering agent for keeping the safe range a buffering agent is appropriately selected from conventionally known various agents and used. Specifically, for example, acids such as phosphoric acid, boric acid, carboxylic acid, and oxycarboxylic acid, and salts thereof (eg, sodium salt), and Good-Buffer
- EDTA ethylenediaminetetraacetic acid
- EDTA-2Na ethylenediaminetetraacetic acid disodium
- EDTA '3Na ethylenediaminetetraacetic acid trisodium
- the ophthalmic composition according to the present invention may contain a conventionally known anion-based surfactant at a concentration that does not impair the action and effect of the present invention.
- Surfactants, amphoteric surfactants, surfactants such as cationic surfactants, It may be added or contained.
- menthol borneol, camphor, geraniol, u-potash oil, bergamot oil, wicket oil, for the purpose of giving a refreshing sensation at the time of instillation and eliminating foreign body itchiness when wearing a contact lens.
- a cooling agent such as heart oil, rose oil or cool mint.
- the ophthalmic composition according to the present invention includes glycyrrhizic acid and salts thereof, ⁇ -aminocaproic acid, allantoin in order to suppress inflammation in the eye caused by stress, wearing of contact lenses, and the like.
- An anti-inflammatory agent such as sodium azulene sulfonate, vitamin B (including retinol palmitate, j3-carotene, etc.), vitamin B
- Vitamin E such as d-hydroxytocopherol acetate
- vitamins such as panthenol
- anti-allergic agents such as cromoglycic acid, sodium cromoglycate, tranilast, potassium dimilorast, aspartic acid and salts thereof
- amino acids such as aminoethylsulfonic acid, arginine, alanine, lysine, and gnoretamic acid can be appropriately added according to the intended use of the ophthalmic composition.
- the powerful ophthalmic composition according to the present invention is prepared by adding and containing the above-mentioned components in appropriate aqueous media in appropriate amounts in the same manner as in the prior art.
- Aqueous media used for this purpose are not only water itself such as tap water, purified water, and distilled water, but also a water-based solution that is highly safe for living organisms and is ophthalmological. It goes without saying that any of these can be used as long as they are sufficiently acceptable.
- preparing the ophthalmic composition according to the present invention containing the above-mentioned components no special method is required, and the aqueous medium is prepared in the same manner as in the case of preparing an ordinary aqueous solution. It can be easily obtained by dissolving each component in
- the eye drop composition according to the present invention obtained as described above is prescribed for eyes having symptoms such as dry eye
- the same as conventionally known eye drops or eye drops is used.
- an appropriate amount may be dropped.
- gelation high viscosity
- the ophthalmic composition according to the present invention is applied to the eye, gelation (high viscosity) occurs due to calcium ions and the like in tears, and the ozone is oxidized.
- a uniform gel layer can be formed, and the osmotic pressure of tears is appropriately adjusted.
- the discomfort and dryness of the eyes are extremely effectively improved, the symptoms of dry eye can be advantageously eliminated, and an excellent feeling in use can be realized.
- the ophthalmic composition according to the present invention does not have any adverse effect on the contact lens, it does not matter whether or not the contact lens is worn when instilling. In particular, if the eye drops are applied when wearing a contact lens, the active ingredient also penetrates and penetrates into the back side of the contact lens, realizing an excellent feeling of wearing the contact lens, and extremely adhering proteins to the contact lens. It can be prevented so that the function of the ophthalmic composition according to the invention is maximized.
- the type of the target contact lens is not limited at all.
- Soft contact lenses and hard contact lenses that are classified into all types, such as water-containing and high water-containing, can be targeted, and there is no question whatsoever when applying the present invention.
- boric acid and borax are used as buffers
- disodium edetate is used as a chelating agent
- 1-menthol is used as a cooling agent
- potassium sorbate is used as a preservative.
- pH and osmotic pressure of each of the obtained ophthalmic compositions were measured, and the obtained results are shown in Tables 1 and 2 below. A sex evaluation test was performed.
- Each ophthalmic composition was applied to 30 volunteers. Then, the corneal surface was observed with a slit lamp microscope, the tear breakup time (BUT) was measured, and the evaluation was performed according to the following evaluation criteria. The results were shown in Tables 1 and 2 below. It was shown to. More specifically, the volunteers blink several times after fluorescein staining, then instruct the eyelid to open, and after a complete blink, the time until the tear film of the corneal epithelium is first destroyed. was measured using a cobalt filter.
- ⁇ : BUT is 10 seconds or more and less than 15 seconds.
- the ophthalmic composition according to Example 1-13 has a dry feeling-reducing effect, a usability test result, and tear wettability. ⁇ This indicates that the symptoms of dry eye can be effectively improved and the feeling of use is excellent.
- the dryness-reducing effect, the usability research result, and the tear wettability were X or ⁇ .
- a contact lens As a contact lens, a one-day accuview (BC 9.0 / P-3.00 / Dia 14.2) manufactured by Johnson 'End' Johnson Co., Ltd. was prepared, and as an ophthalmic composition, Examples 1, 6, and 8 obtained above were used. The compositions for eye drops according to Comparative Examples 3 and 6 were prepared respectively.
- the contact lens was immersed in about 100 ml of physiological saline for 1 hour, the contact lens was taken out from the physiological saline and lightly dried with commercially available paper. Then, each of the contact lenses taken out was immersed in 10 ml of the ophthalmic composition for 5 minutes for 5 minutes each. Next, the contact lens was removed from each ophthalmic composition and lightly dehydrated with commercially available paper.Then, a protein solution having the composition shown in Table 3 below (the FDA artificial tear fluid without lipids) was used. 2 times diluted solution).
- the protein solution in which the contact lens was immersed was agitated with a stirrer, and 200 ⁇ l of the solution was added at regular intervals (20 minutes, 60 minutes, 120 minutes, and 150 minutes). After sampling, high-performance liquid chromatography analysis was performed, and changes over time in the amount of protein attached were examined. Table 4 below shows the amount of protein attached after 150 minutes.
- Comparative Example 6 0.952 Force As is clear from the results in Table 4, in the contact lenses immersed in the ophthalmic compositions according to Examples 1 and 68 in which the A component was blended, the A component was blended. It can be seen that protein adhesion is advantageously suppressed as compared with those of Comparative Examples 3 and 6, which are not performed.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Eyeglasses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005511320A JP4850513B2 (ja) | 2003-07-03 | 2004-06-22 | 点眼用組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003270784 | 2003-07-03 | ||
JP2003-270784 | 2003-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005002595A1 true WO2005002595A1 (ja) | 2005-01-13 |
Family
ID=33562623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/008739 WO2005002595A1 (ja) | 2003-07-03 | 2004-06-22 | 点眼用組成物 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4850513B2 (ja) |
WO (1) | WO2005002595A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006219484A (ja) * | 2005-01-12 | 2006-08-24 | Rohto Pharmaceut Co Ltd | 眼局所適用製剤 |
JP2006248960A (ja) * | 2005-03-10 | 2006-09-21 | Rohto Pharmaceut Co Ltd | 水性外用組成物 |
JP2007176932A (ja) * | 2005-11-30 | 2007-07-12 | Taisho Pharmaceut Co Ltd | 粘膜適用液剤 |
WO2008088612A1 (en) * | 2006-12-20 | 2008-07-24 | Bausch & Lomb Incorporated | Method of stimulating the production of mucin in the eye of a patient |
KR100963611B1 (ko) * | 2008-01-23 | 2010-06-15 | 주식회사태준제약 | 알긴산류 화합물을 포함하는 점안용 조성물 및 그의제조방법 |
US8067038B2 (en) * | 2006-06-16 | 2011-11-29 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic composition for soft contact lens comprising terpenoid |
JP2014515383A (ja) * | 2011-05-27 | 2014-06-30 | レイショファーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | PGF2α類似体を含む眼科用製剤 |
JP2014525891A (ja) * | 2011-04-22 | 2014-10-02 | アルコン リサーチ, リミテッド | 二つの異なる粘性増強剤を有する粘性増強システムを備えた眼科用組成物 |
JP5654704B1 (ja) * | 2014-05-29 | 2015-01-14 | ロート製薬株式会社 | 眼科組成物 |
WO2015156321A1 (ja) * | 2014-04-09 | 2015-10-15 | ロート製薬株式会社 | 眼科組成物 |
JP2015197479A (ja) * | 2014-03-31 | 2015-11-09 | 株式会社メニコン | 眼科用組成液及びその使用方法 |
JP2016088922A (ja) * | 2014-11-12 | 2016-05-23 | ロート製薬株式会社 | 眼科組成物 |
CN106163565A (zh) * | 2014-04-09 | 2016-11-23 | 乐敦制药株式会社 | 眼科组合物 |
JP2020075918A (ja) * | 2018-11-02 | 2020-05-21 | 千寿製薬株式会社 | 角膜上皮創傷治癒促進用の眼科用組成物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63159821A (ja) * | 1986-12-23 | 1988-07-02 | Tome Sangyo Kk | コンタクトレンズ用洗浄剤 |
JPH07157747A (ja) * | 1993-12-10 | 1995-06-20 | Hoya Corp | コンタクトレンズ用剤 |
WO1997028827A1 (fr) * | 1996-02-07 | 1997-08-14 | Rohto Pharmaceutical Co., Ltd. | Composition ophtalmique possedant une viscosite adaptee |
JPH11180858A (ja) * | 1997-12-18 | 1999-07-06 | Rohto Pharmaceut Co Ltd | 清涼化剤を含有するコンタクトレンズ用点眼剤 |
JP2000159659A (ja) * | 1998-11-30 | 2000-06-13 | Kazuo Tsubota | 眼科用人工涙液 |
JP2001228445A (ja) * | 2000-12-13 | 2001-08-24 | Rohto Pharmaceut Co Ltd | コンタクトレンズ用溶剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4287175A (en) * | 1978-06-22 | 1981-09-01 | Merck & Co., Inc. | Contact lens wetting agents |
JP4294252B2 (ja) * | 2001-03-08 | 2009-07-08 | ロート製薬株式会社 | Gリッチなアルギン酸含有組成物 |
JP3974431B2 (ja) * | 2001-03-08 | 2007-09-12 | ロート製薬株式会社 | アルギン酸含有組成物 |
JP4099624B2 (ja) * | 2001-04-24 | 2008-06-11 | ライオン株式会社 | ソフトコンタクトレンズ用組成物 |
-
2004
- 2004-06-22 JP JP2005511320A patent/JP4850513B2/ja not_active Expired - Lifetime
- 2004-06-22 WO PCT/JP2004/008739 patent/WO2005002595A1/ja active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63159821A (ja) * | 1986-12-23 | 1988-07-02 | Tome Sangyo Kk | コンタクトレンズ用洗浄剤 |
JPH07157747A (ja) * | 1993-12-10 | 1995-06-20 | Hoya Corp | コンタクトレンズ用剤 |
WO1997028827A1 (fr) * | 1996-02-07 | 1997-08-14 | Rohto Pharmaceutical Co., Ltd. | Composition ophtalmique possedant une viscosite adaptee |
JPH11180858A (ja) * | 1997-12-18 | 1999-07-06 | Rohto Pharmaceut Co Ltd | 清涼化剤を含有するコンタクトレンズ用点眼剤 |
JP2000159659A (ja) * | 1998-11-30 | 2000-06-13 | Kazuo Tsubota | 眼科用人工涙液 |
JP2001228445A (ja) * | 2000-12-13 | 2001-08-24 | Rohto Pharmaceut Co Ltd | コンタクトレンズ用溶剤 |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006219484A (ja) * | 2005-01-12 | 2006-08-24 | Rohto Pharmaceut Co Ltd | 眼局所適用製剤 |
JP2006248960A (ja) * | 2005-03-10 | 2006-09-21 | Rohto Pharmaceut Co Ltd | 水性外用組成物 |
JP2007176932A (ja) * | 2005-11-30 | 2007-07-12 | Taisho Pharmaceut Co Ltd | 粘膜適用液剤 |
US8067038B2 (en) * | 2006-06-16 | 2011-11-29 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic composition for soft contact lens comprising terpenoid |
USRE43583E1 (en) * | 2006-06-16 | 2012-08-14 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic composition for soft contact lens comprising terpenoid |
WO2008088612A1 (en) * | 2006-12-20 | 2008-07-24 | Bausch & Lomb Incorporated | Method of stimulating the production of mucin in the eye of a patient |
KR100963611B1 (ko) * | 2008-01-23 | 2010-06-15 | 주식회사태준제약 | 알긴산류 화합물을 포함하는 점안용 조성물 및 그의제조방법 |
JP2014525891A (ja) * | 2011-04-22 | 2014-10-02 | アルコン リサーチ, リミテッド | 二つの異なる粘性増強剤を有する粘性増強システムを備えた眼科用組成物 |
JP2014515383A (ja) * | 2011-05-27 | 2014-06-30 | レイショファーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | PGF2α類似体を含む眼科用製剤 |
JP2015197479A (ja) * | 2014-03-31 | 2015-11-09 | 株式会社メニコン | 眼科用組成液及びその使用方法 |
WO2015156321A1 (ja) * | 2014-04-09 | 2015-10-15 | ロート製薬株式会社 | 眼科組成物 |
CN106163565A (zh) * | 2014-04-09 | 2016-11-23 | 乐敦制药株式会社 | 眼科组合物 |
JP5654704B1 (ja) * | 2014-05-29 | 2015-01-14 | ロート製薬株式会社 | 眼科組成物 |
JP2015199697A (ja) * | 2014-05-29 | 2015-11-12 | ロート製薬株式会社 | 眼科組成物 |
JP2016088922A (ja) * | 2014-11-12 | 2016-05-23 | ロート製薬株式会社 | 眼科組成物 |
JP2020075918A (ja) * | 2018-11-02 | 2020-05-21 | 千寿製薬株式会社 | 角膜上皮創傷治癒促進用の眼科用組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP4850513B2 (ja) | 2012-01-11 |
JPWO2005002595A1 (ja) | 2006-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5472402B2 (ja) | ソフトコンタクトレンズ用組成物及び吸着抑制方法 | |
WO2005002595A1 (ja) | 点眼用組成物 | |
JP4739022B2 (ja) | 眼科用組成物 | |
JP3142842B1 (ja) | 眼科用組成物及びソフトコンタクトレンズへの吸着抑制方法 | |
JP4099624B2 (ja) | ソフトコンタクトレンズ用組成物 | |
JP4751482B2 (ja) | コンタクトレンズ用液剤 | |
WO2004084877A1 (ja) | 眼科用組成物 | |
JP5235420B2 (ja) | ソフトコンタクトレンズ用点眼・装着液 | |
JP2008209677A (ja) | 殺菌剤不活化液剤 | |
JP5731046B1 (ja) | コンタクトレンズ用組成物 | |
JP5678530B2 (ja) | ソフトコンタクトレンズ用眼科組成物 | |
JP2010204597A (ja) | ソフトコンタクトレンズ用組成物及びソフトコンタクトレンズへの吸着抑制方法 | |
JP5587359B2 (ja) | コンタクトレンズ用組成物 | |
JP2005008568A (ja) | 眼科用組成物 | |
JP4981181B1 (ja) | コンタクトレンズ用組成物 | |
JP2006000170A (ja) | コンタクトレンズ用組成物 | |
JP2005172912A (ja) | ソフトコンタクトレンズの装着方法及び装着液原液、並びにコンタクトレンズキット | |
JP4273297B2 (ja) | ソフトコンタクトレンズの含水率低下防止用組成物、及びソフトコンタクトレンズの含水率低下防止方法 | |
WO2005023283A1 (ja) | 眼科用組成物 | |
JP4646807B2 (ja) | 眼科用組成物 | |
WO2011070613A1 (ja) | コンタクトレンズ用組成物、及びそれを用いた負の相互作用の抑制方法 | |
WO2004082673A1 (ja) | 眼科用液剤組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005511320 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |